Endocrine therapy for prostate cancer

References

• Huggins C, Hodges CV. Studies on prostate cancer. 1. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297
   Google Scholar
• Varenhorst E. Prostate cancer treatment: Tolerance of different endocrine regimens. New Development in Biosciences 4, Endocrine management of prostatic cancer, H Klosterhalfen. Walter Gruyter, Berlin, New York 1988; 105–113
   Google Scholar
• Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61: 32–8
   PubMed Web of Science ®Google Scholar
• Hedlund, PO, Henriksson, P, and the, Scandinavian Prostate Cancer Group (SPCG) –5 Trial Study. Parenteral oestrogen versus total androgen ablation in the treatment of advanced prostate carcinoma. Effects on overall survival and cardiovascular mortality. Urology 2000;55:328–333.
   PubMed Web of Science ®Google Scholar
• Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 2004; 5: 2171–9
   PubMed Web of Science ®Google Scholar
• Schröder FH. Cyproterone acetate: mechanism of action and clinical effectivness in prostate cancer treatment. Cancer 1993; 72: 3810–15
   PubMed Web of Science ®Google Scholar
• Tyrell CJ. Casodex: a pure non-steroidal antiandrogen used as monotherapy in advanced prostate cancer. Prostate 1992; Suppl 5: 97–105
   Google Scholar
• Reese DM. Choice of hormonal therapy for prostate cancer. Lancet 2000; 355: 1474–5
   PubMedGoogle Scholar
• Cassileth BR, Soloway MS, Vogelzang NJ. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1992; 1: 323–9
   PubMedGoogle Scholar
• Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients’ choice of treatment in stage D prostate cancer. Urology 1989; 33: 57–62
   PubMed Web of Science ®Google Scholar
• Byar DP. The Veterans Administration Cooperative Urological research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126–30
   PubMed Web of Science ®Google Scholar
• Talbäck M, Stenbeck M, Rosen M, Barlow L, Glimelius B. Cancer survival in Sweden 1960–1998 – Development across four decades. Acta Oncol 2003; 42: 637–59
   PubMed Web of Science ®Google Scholar
• Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 1984; 5: 1–17
   PubMed Web of Science ®Google Scholar
• Eng MH, Charles LG, Ross BD, et al. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 1999; 54: 1112–9
   PubMedGoogle Scholar
• Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687–91
   PubMed Web of Science ®Google Scholar
• Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937–46
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–8
   PubMed Web of Science ®Google Scholar
• Granfors T, Modig H, Damber J-E, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998; 159: 2030–4
   PubMedGoogle Scholar
• Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavourable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997; 5: 1013–21
   Google Scholar
• Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med 1997; 337: 295–300
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781–8
   PubMed Web of Science ®Google Scholar
• The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235–46.
   PubMedGoogle Scholar
• Kirk, D. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation?. Br J Urol 2000;86((suppl 3)):220, (Abstr MP6.1.07)
   Google Scholar
• Kurth, KH. Early versus delayed endocrine treatment in node positive disease. Proc PACIOU VII/DUA VII: an update on sexual function in the elderly male, BPH, renal cancer and prostate cancer and basic science on prostate cancer. 2002;117–8.
   Google Scholar
• See WA, McLeod D, Iversen P, Wirth M. The bicalutamide Early Prostate Cancer Program: Demography. Urol Oncol 2001; 6: 43–7
   PubMedGoogle Scholar
• See WA, Wirth MP, McLeod DG, et al. Bicalutamide (‘Casodex’) 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002; 168: 429–35
   PubMed Web of Science ®Google Scholar
• Wirth MP, See WA, McLeod D, Iversen P, Morris T, Caroll K. On behalf of the Casodex early prostate cancer trialists’ group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Result from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865–70
   PubMed Web of Science ®Google Scholar
• Iversen P, Johansson J-E, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, et al. On behalf of the Scandinavian Prostatic Cancer Group. J Urol 2004; 172: 1871–76
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LHRH agonist or orchidectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem Mol Biol 1985; 23: 833–41
   Google Scholar
• Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systemic Review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 361–76
   PubMed Web of Science ®Google Scholar
• Schmitt, B, Bennett, C, Seidenfeldt, J, Samson, D, Wilt, T. Maximal androgen blockade for advanced prostate cancer (Cochrane Review). The Cochrane Library 2004, Issue 4.
   Google Scholar
• Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275–82
   PubMed Web of Science ®Google Scholar
• Trachtenberg J. Experimental treatment of prostatic cancer by intermittent hormonal therapy. J Urol 1987; 137: 785–8
   PubMed Web of Science ®Google Scholar
• Albrecht W, Collette L, Fava C, Kariakine OB, Whelan P, Studer UE, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study. Eur Urol 2003; 44: 505–11
   PubMed Web of Science ®Google Scholar